Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) — Market Cap & Net Worth
Market Cap & Net Worth: Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has a market capitalization of $198.14 Million ($198.14 Million) as of August 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16602 globally and #3896 in its home market, demonstrating a 25.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arcturus Therapeutics Holdings Inc's stock price $7.41 by its total outstanding shares 28423069 (28.42 Million). See reinvestment intensity of Arcturus Therapeutics Holdings Inc to understand how much of operating cash flow is reinvested back into capital assets.
Arcturus Therapeutics Holdings Inc Market Cap History: 2015 to 2026
Arcturus Therapeutics Holdings Inc's market capitalization history from 2015 to 2026. Data shows change from $1.25 Billion to $210.61 Million (-15.54% CAGR).
Index Memberships
Arcturus Therapeutics Holdings Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.50 Trillion | 0.01% | #458 of 976 |
|
NASDAQ Composite
IXIC
|
$40.86 Trillion | 0.00% | #1637 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.74 Trillion | 0.01% | #227 of 263 |
Weight: Arcturus Therapeutics Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arcturus Therapeutics Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arcturus Therapeutics Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.59x
Arcturus Therapeutics Holdings Inc's market cap is 2.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $417.82 Million | $20.38 Million | -$24.60 Million | 20.50x | N/A |
| 2017 | $225.96 Million | $13.00 Million | -$10.90 Million | 17.38x | N/A |
| 2018 | $128.76 Million | $15.75 Million | -$21.79 Million | 8.17x | N/A |
| 2019 | $308.96 Million | $20.79 Million | -$25.99 Million | 14.86x | N/A |
| 2020 | $1.23 Billion | $9.54 Million | -$72.15 Million | 129.26x | N/A |
| 2021 | $1.05 Billion | $12.36 Million | -$203.67 Million | 85.12x | N/A |
| 2022 | $482.06 Million | $205.75 Million | $9.35 Million | 2.34x | 51.56x |
| 2023 | $896.18 Million | $157.75 Million | -$29.73 Million | 5.68x | N/A |
| 2024 | $482.34 Million | $138.39 Million | -$80.94 Million | 3.49x | N/A |
| 2025 | $174.23 Million | $67.22 Million | -$65.78 Million | 2.59x | N/A |
Competitor Companies of ARCT by Market Capitalization
Companies near Arcturus Therapeutics Holdings Inc in the global market cap rankings as of August 10, 2026.
Key companies related to Arcturus Therapeutics Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #547 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #555 globally with a market cap of $48.81 Billion USD ( ₩72.03 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $496.07 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $784.36 |
| #547 | Argen-X | BR:ARGX | $49.55 Billion | €763.20 |
| #555 | Samsung Biologics Co Ltd | KO:207940 | $48.81 Billion | ₩1556000.00 |
Arcturus Therapeutics Holdings Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Arcturus Therapeutics Holdings Inc's market cap moved from $1.25 Billion to $ 210.61 Million, with a yearly change of -15.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $210.61 Million | +20.88% |
| 2025 | $174.23 Million | -63.88% |
| 2024 | $482.34 Million | -46.18% |
| 2023 | $896.18 Million | +85.91% |
| 2022 | $482.06 Million | -54.17% |
| 2021 | $1.05 Billion | -14.68% |
| 2020 | $1.23 Billion | +299.08% |
| 2019 | $308.96 Million | +139.96% |
| 2018 | $128.76 Million | -43.02% |
| 2017 | $225.96 Million | -45.92% |
| 2016 | $417.82 Million | -66.56% |
| 2015 | $1.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 9th, 2026 the market cap of Arcturus Therapeutics Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $198.14 Million USD |
| MoneyControl | $198.14 Million USD |
| MarketWatch | $198.14 Million USD |
| marketcap.company | $198.14 Million USD |
| Reuters | $198.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more